

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO. <b>4821-523-999</b>	APPLICATION NO <b>10/665,430</b>
		APPLICANT <b>Paul D. RUBIN et al.</b>	
		FILING DATE <b>September 22, 2003</b>	GROUP <b>To Be Assigned</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Q T	A01	6,331,536	12/2001	Radulovacki et al.	514	214.02	
	A02	6,071,928	1/2000	Curtis et al.	514	278	
	A03	6,048,879	4/2000	Rubin et al.	514	327	
	A04	5,733,566	3/1998	Lewis	424	426	
	A05	5,712,302	1/1998	Young	514	397	
	A06	5,674,533	10/1997	Santus et al.	424	493	
	A07	5,639,476	6/1997	Oshlack et al.	424	468	
	A08	5,591,767	1/1997	Mohr et al.	514	413	
	A09	5,561,149	10/01/96	Azria et al.	514	397	
	A10	5,519,044	05/21/96	Imperato et al.	514	397	
	A11	5,502,067	3/1996	Morgan	514	397	
	A12	5,445,604	08/29/95	Lang	602	47	
	A13	5,422,374	6/1995	Miyo et al.	514	690	
	A14	5,407,953	4/1995	Morgan	514	397	
	A15	5,356,934	10/1994	Robertson et al.	514	649	
	A16	5,354,556	10/1994	Sparks et al.	424	419	
	A17	5,198,447	03/30/93	Tyers	514	304	
	A18	5,120,548	1/1992	McClelland et al.	424	473	
	A19	5,098,909	03/24/92	Williams	514	286	
	A20	5,075,290	12/1991	Findley et al.	514	46	
	A21	5,073,543	12/1991	Marshall et al.	514	21	
	A22	5,059,595	10/1991	Le Grazie	424	468	
	A23	4,929,632	5/1990	Tyers et al.	514	397	
	A24	4,851,407	06/25/89	Wootton et al.	514	213	
	A25	4,845,115	07/04/89	Tyers	514	397	
Q T	A26	4,835,173	05/30/89	Tyers	514	397	

EXAMINER	Q T	DATE CONSIDERED	8/08/05
----------	-----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO.	10/665 430 APPLICATION NO
		4821-523-999	To Be Assigned
		APPLICANT	
		Paul D. RUBIN et al.	
FILING DATE	GROUP		
Concurrently Herewith	To Be Assigned		

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S.T	A27	4,764,515	06/16/88	Borsa et al.	514	255	
	A28	4,753,789	6/1988	Tyres et al.	424	10	
	A29	4,695,578	9/1987	Coates et al.	514	397	
	A30	4,598,084	07/01/86	Strolin-Benedetti et al.	514	374	
	A31	4,008,719	2/1977	Theeuwes et al.	128	260	
	A32	3,961,073	06/01/76	Snyder	424	325	
	A33	3,916,899	11/1975	Theeuwes et al.	128	260	
	A34	3,845,770	11/1974	Theeuwes et al.	128	260	
	A35	3,598,123	8/1971	Zaffaroni	128	268	
S.T	A36	3,536,809	10/1970	Applezweig	424	28	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
S.T	B01	WO 99/43319	09/02/1999	WIPO	WT				
S.T	B02	WO 93 00075 A	01/07/93	WIPO	WD				
S.T	B03	WO 91 07175 A	05/30/91	WIPO	WD				
	B04	WO 91 02524 A	03/07/91	WIPO	WD				X
S.T	B05	EP 0 411 900 A2	02/06/91	Europe					
S.T	B06	EP 0 201 165 A	11/12/86	Europe					
S.T	B07	EP 0 052 492	05/26/82	Europe					
S.T	B08	EP 0 100 569 A	02/15/84	Europe					
S.T	B09	GB 2 153 821 A	08/29/85	United Kingdom					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

S.T	C01	Stedman's Medical Dictionary, 27 <sup>th</sup> Edition
S.T	C02	Stedman's Medical Dictionary, 26 <sup>th</sup> Edition, 1995, P. 114.
S.T	C03	Phillis, J. W., "Monoamines in the Central Nervous System," <u>The Pharmacology of Synapses</u> , 1970, Monograph, P. 43.

EXAMINER	S.T	DATE CONSIDERED 8/8/05
----------	-----	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 4821-523-999	APPLICATION NO 10/665,430 To Be Assigned
	APPLICANT Paul D. RUBIN et al.	
	FILING DATE Concurrently Herewith	GROUP To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
S.T	C04	Frazer, A., et al., <i>Annual Rev. of Pharmacology and Therapeutics</i> , 1990, vol. 30, Pp. 307-348.
	C05	Naylor, R. J., et al., <i>Euro. J. Anaesth.</i> , 1976, vol. 9, Pp. 3-10.
	C06	Desai, K. M., et al., <i>Br. J. Pharmacol.</i> , 1994, vol. 111, Pp. 346-350.
	C07	Fozard, J. H., et al., <i>Br. J. Pharmacol.</i> , 1976, vol. 57, Pp. 115-125.
	C08	Kim, M. Y., et al., <i>Heterocycles</i> , 1997, vol. 45(10), Pp. 2041-2043.
	C09	Lochmuller, C. H., et al., <i>J. Chromatogr.</i> , 1975, vol. 113(3), Pp. 283-302.
	C10	Ebert, W. R., <i>Pharm. Tech.</i> , 1977, vol. 1(5), Pp. 44-50.
	C11	Burstein, E. S., et al., <i>J. Biol. Chem.</i> , 1995, vol. 270, Pp. 3141-3146.
	C12	Messier, T. L., et al., <i>Pharmacol. Toxicol.</i> , 1995, vol. 76(5), Pp. 308-311.
	C13	Bradley, P. B., et al., <i>Neuropharmacology</i> , 1986, vol. 25, Pp. 563-576.
	C14	Dumuis, A., et al., <i>N. S. Arch. Pharmacol.</i> , 1989, vol. 340, Pp. 403-410.
	C15	Miyata, K., et al., <i>J. Pharmacol. Exp. Ther.</i> , 1991, vol. 259, Pp. 815-819.
	C16	Cohen, M. L., et al., <i>J. Pharmacol. Exp. Ther.</i> , 1989, vol. 248, Pp. 197-201.
	C17	Berkow, R. et al. <i>The Merck Manual</i> , 1997, Pp. 154-155, 304-305, 1205-1206.
	C18	Eliel, E. <i>Stereochemistry of Carbon Compounds</i> , 1962, Pp. xi-xv.
	C19	Ariens, E.J., "Stereoselectivity in Pharmacodynamics and Pharmacokinetics," <i>Schweiz. Med. Wochnshsr.</i> , vol. 120, no. 5, pages 131-134, February 3, 1990.
	C20	Ariens, E.J., "Racemic Therapeutics - Ethical and Regulatory Aspects," <i>Eur. J. Clin. Pharmacol.</i> , vol. 41, no. 2, pages 89-93, 1991.
	C21	Ariens, E.J., "Racemische Therapeutica Probleemniddelen," <i>Pharmaceutisch Weekblad</i> , vol. 125, no. 2, pages 552-554, June 1, 1990 (Abstract).
	C22	Butler, A. et al., "Pharmacological Properties of GR38032F, A Novel Antagonist at 5-HT3 Receptors," <i>Br. J. Pharmacol.</i> , vol. 94, pages 397-412, June 1, 1990.
	C23	Butler, A., "The Pharmacological Characterization of 5-HT3 Receptors in Three Isolated Preparations Derived From Guinea-Pig Tissues," <i>Br. J. Pharmacol.</i> , vol. 101, pages 591-598, 1990.
S.T	C24	De Mulder, P.H.M. et al., "Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting," <i>Annals of Internal Medicine</i> , vol. 113, no. 11, pages 834-840, December 1, 1990. (Abstract)

EXAMINER	S.T	DATE CONSIDERED	8/8/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO.	10/6/85 430 APPLICATION NO.
	4821-523-999	To Be Assigned
	APPLICANT	Paul D. RUBIN et al.
	FILING DATE	GROUP Concurrently Herewith To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
9 IT	C25	Graves, T., "Chemotherapy-induced nausea and vomiting: Treatment options," Hosp. Formul., vol. 26, pages 474-476, 478-480, 485, 488, June 1991. (Abstract)
	C26	Hibert, M.F. et al., "Conformation-Activity Relationship Study of 5-HT3 Receptor Antagonists and a Definition of a Model for This Receptor Site," J. Med. Chem. vol. 33, no. 6, pages 1594-1600, 1990.
	C27	Kusnirczyk, H. et al., "Antitumor Activity of Optical Isomers of Cyclophosphamide, Ifosfamide and Trofosfamide as Compared to Clinically Used Racemats," Journal of Immunopharmacology, vol. 8, no. 4, pages 455-480, 1986. (Abstract)
	C28	Nukariya, N. et al., "Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs-dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs." Gan To Kagaku Ryoho, vol. 19, mo. 9, pages 1347-1357, August 1992. (Abstract)
	C29	Nukariya et al., "Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs," Gan go Kagaku Ryoho, vol. 19, no. 9, pages 1375-1385, August 1992. (Abstract)
	C30	Pinkerton, C.R. et al., "5-HT3 antagonist ondansetron - an effective outpatient antiemetic in cancer treatment," Arch. Dis. Child., vol. 65, no. 8, pages 822-825, August 1990. (Abstract)
	C31	Stevens, R.F., "The Role of Ondansetron in Paediatric Patients: A Review of Three Studies," Eur. J. Cancer, vol. 27, no. Suppl. 1, pages S20-S22, 1991. (Abstract)
	C32	Testa, B. et al., "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?" Chirality, vol. 2, pages 129-133, 1990.
	C33	Tonato, M., "Ondansetron Plus Dexamethasone: An Effective Combination in High-dose Cisplatin Therapy," Eur. J. Cancer, vol. 27, no. Suppl 1, pages S12-S14, 1991. (Abstract)
	C34	M. Radulovacki et al., Serotonin 5-HT3-Receptor Antagonist GR 38023F Suppresses Sleep Apneas in Rats, Sleep, vol. 21, no. 2, March 15, 1998, pages 131-136, Allen Press, Lawrence, KA..
	C35	M. Yoshioka, et al., Pharmacological Characterization of 5-Hydroxytryptamine-Induced Apnea in the Rat, J. of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, 1992, pages 917-924.
9 IT	C36	Y. Goda, et al., The Role of 5-HT3 Receptor Mediated Mechanisms on SHT-3 Induced Apnea in Anesthetized Rats, European Journal of Pharmacology, vol. 183, no. 3, 1990, pages 705-706.

EXAMINER	9 IT	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		